It is an adenosine diphosphate (ADP) P2Y12 receptor antagonist. This first-generation drug has only recently been developed and put on the market, making it unlikely to be widely extended for post-PCI surgery medication.
Continuous new drug development and introduction not only treat diseases but also greatly promote the progress of surgery, ensuring patients' preoperative, intraoperative, and postoperative stability.
The other classmates saw her suddenly fall silent, wondering what was going on with her.
Xie Wanying was just considering that if this patient delayed a few more years, there might be a chance for DAPT therapy and the introduction of drug-coated stents.
